Business
CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
-- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-tr...
About this update from Prime Drink Group Corp
[{"type":"text","content":"CORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates\n\n\n\n\n -- New preclinical data for PM577 in Wilson’s Disease (WD) to be presented at AASLD; on-track to file IND and/or CTA in H1’26, with initial clinical data expected in 2027 --\n \n\n\n\n -- Nominated PM647 as development candidate for Alpha-1 Antitrypsin Deficiency (AATD); on-track to file IND and/or CTA in mid-2026, with initial clinical data expected in 2027 --\n \n\n\n\n -- Strengthened leadership team with the appointment of Matthew Hawryluk, Ph.D., M.B.A. as Chief Business Officer --\n \n\n\n\n --\n \n\n Company to host virtual KOL event at 8:00am ET on Wednesday, November 12, 2025 to showcase Wilson’s Disease Strategy --\n \n\n\n CAMBRIDGE, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- In a release issued earlier today by Prime Medicine, Inc. (Nasdaq: PRME) under the same headline, please note the first paragraph under \"Prime Medicine’s Pipeline\" has been amended to include \"Prime Medicine expects to file an investigational new drug application (IND) and/or clinical trial application (CTA) for its WD program in the first half of 2026\" rather than the \"first half of 2027\" as originally issued. Corrected release follows.\n \n\n Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the quarter ended September 30, 2025 and provided a business update.\n \n\n “We remain steadfast in executing our focused strategy, with efforts centered on advancing our liver-targeted programs in WD and AATD, our Cystic Fibrosis (CF) program as well as exploring additional collaborations – like our efforts with Bristol Myers Squibb – that can expand the reach and impact of our technology,” said Allan Reine, M.D., Chief Executive Officer of Prime Medicine. “In recent months, we’ve made meaningful progress across these priorities. In August, we nominated PM647 as our development candidate for AATD, marking a significant step toward delivering a best-in-class therapy capable of correcting the mutant AATD protein back to normal. And, earlier this week, we welcomed Matthew Hawryluk, Ph.D., M.B.A., as Chief Business Officer, adding a senior ...